Skip to main content
KALA BIO, Inc. logo

KALA BIO, Inc. — Investor Relations & Filings

Ticker · KALA ISIN · US4831192020 LEI · 529900Y7RO0C9P0TX474 US Manufacturing
Filings indexed 643 across all filing types
Latest filing 2026-04-15 Annual Report
Country US United States of America
Listing US KALA

About KALA BIO, Inc.

https://www.kalarx.com/

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for rare and severe eye diseases. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to create therapies with regenerative healing effects. Its lead product candidate, KPI-012, is a topical therapy in a Phase 2b clinical study for the treatment of persistent corneal epithelial defect (PCED), for which it has received Orphan Drug and Fast Track designations from the U.S. FDA. The pipeline also includes KPI-014, a preclinical, gene-agnostic intravitreal therapy being developed for inherited retinal degenerations. Following the sale of its commercial products in 2022, KALA BIO has concentrated its efforts on advancing its biologics pipeline for ophthalmic conditions.

Recent filings

Filing Released Lang Actions
10-K - KALA BIO, Inc. (0001479419) (Filer)
Annual Report FY 2025
2026-04-15 English
D - KALA BIO, Inc. (0001479419) (Filer)
Regulatory Filings
2026-03-17 English
144 - KALA BIO, Inc. (0001479419) (Subject)
Regulatory Filings
2026-03-17 English
8-K - KALA BIO, INC. (0001479419) (Filer)
Regulatory Filings
2026-03-04 English
8-K - KALA BIO, INC. (0001479419) (Filer)
Regulatory Filings
2026-02-20 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.